ChromaDex Corp (NAS:CDXC)
$ 3.8 0.02 (0.53%) Market Cap: 288.55 Mil Enterprise Value: 263.94 Mil PE Ratio: 0 PB Ratio: 9.34 GF Score: 74/100

Q3 2023 Chromadex Corp Earnings Call Transcript

Nov 08, 2023 / 09:30PM GMT
Release Date Price: $1.6 (+4.58%)
Operator

Hello and thank you for standing by. My name is Regina, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the ChromaDex Corporation third quarter 2023 earnings conference call. (Operator Instructions)

I would now like to turn the conference over to Kendall Knysch, Head of Public Relations and Partnerships. Please go ahead.

Kendall Knysch
ChromaDex Corporation - Director of Media Relations

Thank you. Good afternoon and welcome to ChromaDex Corporation's third quarter 2023 results investor call. With us today are ChromaDex's Chief Executive Officer, Rob Fried; Chief Financial Officer, Brianna Gerber; and Senior Vice President of Scientific and Regulatory Affairs, Dr. Andrew Shao, who will join the call for Q&A.

Today's conference call may include forward-looking statements, including statements related to ChromaDex's research and development and clinical trial plans and the timing and results of such trials. The timing of future regulatory filings, the expansion of the sale of Tru Niagen in new

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot